학술논문

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort
Document Type
Academic Journal
Author
Abdul-Aziz, Mohd H.Lipman, JeffreyAkova, MuratBassetti, MatteoDe Waele, Jan J.Dimopoulos, GeorgeDulhunty, JoelKaukonen, Kirsi-MaijaKoulenti, DespoinaMartin, ClaudeMontravers, PhilippeRello, JordiRhodes, AndrewStarr, ThereseWallis, Steven C.Roberts, Jason A.Roberts, Jason A.Lipman, JeffreyStarr, ThereseWallis, Steven C.Paul, SanjoyRibas, Antonio MargaritDe Waele, Jan J.De Crop, LucSpapen, HerbertWauters, JoostDugernier, ThierryJorens, PhilippeDapper, IlseDe Backer, DanielTaccone, Fabio S.Rello, JordiRuano, LauraAfonso, ElsaAlvarez-Lerma, FranciscoGracia-Arnillas, Maria PilarFernández, FranciscoFeijoo, NeusBardolet, NeusRovira, AssumptaGarro, PauColon, DianaCastillo, CarlosFernado, JuanLopez, Maria JesusFernandez, Jose LuisArribas, Ana MariaTeja, Jose LuisOts, ElsaMontejo, Juan CarlosCatalan, MercedesPrieto, IsidroGonzalo, GloriaGalvan, BeatrizBlasco, Miguel AngelMeyer, EstibalizDel Nogal, FrutosVidaur, LoretoSebastian, RosaGarde, Pila Marcodel Mar Martin Velasco, MariaCrespo, Rafael ZaragozaEsperatti, MarianoTorres, AntoniMontravers, PhilippeBaldesi, OlivierDupont, HerveMahjoub, YazineLasocki, SigismondConstantin, Jean MichelPayen, Jean FrançoisMartin, ClaudeAlbanese, JacquesMalledant, YannickPottecher, JulienLefrant, Jean-YvesJaber, SamirJoannes-Boyau, OlivierOrban, ChristopheOstermann, MarliesMcKenzie, CatherineBerry, WillaimSmith, JohnLei, KatieRubulotta, FrancescaGordon, AnthonyBrett, StephenStotz, MartinTempleton, MaieRhodes, AndrewEbm, ClaudiaMoran, CarlKaukonen, Kirsi-MaijaPettilä, VilleDimopoulos, GeorgeKoulenti, DespoinaXristodoulou, AglaiaTheodorou, VassilikiKouliatsis, GeorgiosSertaridou, EleniAnthopoulos, GeorgiosChoutas, GeorgeRantis, ThanosKaratzas, StylianosBalla, MargaritaPapanikolaou, MetaxiaMyrianthefs, PavlosGavala, AlexandraFildisis, GeorgiosKoutsoukou, AntoniaKyriakopoulou, MagdaliniPetrochilou, KalomoiraKompoti, MariaMichalia, MarthaClouva-Molyvdas, Fillis-MariaGkiokas, GeorgiosNikolakopoulos, FotiosPsychogiou, VasilikiMalliotakis, PolychronisAkoumianaki, EvangeliaLilitsis, EmmanouilKoulouras, VassiliosNakos, GeorgeKalogirou, MihalisKomnos, ApostolosZafeiridis, TilemachosChaintoutis, ChristosArvaniti, KostoulaMatamis, DimitriosChaintoutis, ChristosKydona, ChristinaGritsi-Gerogianni, NikoletaGiasnetsova, TatianaGiannakou, MariaSoultati, IoannaChytas, IliasAntoniadou, EleniAntipa, ElliLathyris, DimitriosKoukoubani, TriantafylliaParaforou, TheonikiSpiropoulou, KyriakiBekos, VasileiosSpring, AnnaKalatzi, TheodoraNikolaou, HaraLaskou, MariaStrouvalis, IoannisAloizos, StavrosKapogiannis, SpyridonSoldatou, OuraniaBassetti, MatteoAdembri, ChiaraVilla, GianlucaGiarratano, AntonioRaineri, Santi MaurizioCortegiani, AndreaMontalto, FrancescaStrano, Maria TeresaRanieri, V. MarcoSandroni, ClaudioDe Pascale, GennaroMolin, AlexandrePelosi, PaoloMontagnani, LucaUrbino, RosarioMastromauro, IlariaDe Rosa, Francesco G.Ranieri, V. MarcoCardoso, TeresaAfonso, SusanaGonçalves-Pereira, JoãoBaptista, João PedroAkova, MuratÖzveren, Arife
Source
Journal of Antimicrobial Chemotherapy. Jan 01, 2016 71(1):196-207
Subject
Language
English
ISSN
0305-7453
Abstract
OBJECTIVES: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged-infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. METHODS: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. RESULTS: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DALI study, 182 met inclusion criteria. Overall, 89.0% (162/182) of patients achieved the most conservative target of 50% fT>MIC (time over which unbound or free drug concentration remains above the MIC). Decreasing creatinine clearance and the use of prolonged infusion significantly increased the PTA for most pharmacokinetic/pharmacodynamic targets. In the subgroup of patients who had respiratory infection, patients receiving β-lactams via prolonged infusion demonstrated significantly better 30 day survival when compared with intermittent-bolus patients [86.2% (25/29) versus 56.7% (17/30); P = 0.012]. Additionally, in patients with a SOFA score of ≥9, administration by prolonged infusion compared with intermittent-bolus dosing demonstrated significantly better clinical cure [73.3% (11/15) versus 35.0% (7/20); P = 0.035] and survival rates [73.3% (11/15) versus 25.0% (5/20); P = 0.025]. CONCLUSIONS: Analysis of this large dataset has provided additional data on the niche benefits of administration of piperacillin/tazobactam and meropenem by prolonged infusion in critically ill patients, particularly for patients with respiratory infections.